Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update
International Journal of Molecular Sciences · 15.03.2023 · 24 (6) · 5643
DOI: 10.3390/ijms24065643 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.03.2023. Verfasst von Quang Minh Dang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Rheumatic Diseases, Arthritis, Rheumatoid, Neoplasms, Myositis. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 180 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, a Grant for Promoting Research and Survey in Rheumatic Diseases by Japan Rheumatism Foundation, Grant for Promoting Research and Survey in Rheumatic Diseases by Japan Rheumatism Foundation to RW.
Themen: Patientensicherheit
Abstract (Originalsprache)
With the aging of the population, malignancies are becoming common complications in patients with rheumatoid arthritis (RA), particularly in elderly patients. Such malignancies often interfere with RA treatment. Among several therapeutic agents, immune checkpoint inhibitors (ICIs) which antagonize immunological brakes on T lymphocytes have emerged as a promising treatment option for a variety of malignancies. In parallel, evidence has accumulated that ICIs are associated with numerous immune-related adverse events (irAEs), such as hypophysitis, myocarditis, pneumonitis, and colitis. Moreover, ICIs not only exacerbate pre-existing autoimmune diseases, but also cause de novo rheumatic disease–like symptoms, such as arthritis, myositis, and vasculitis, which are currently termed rheumatic irAEs. Rheumatic irAEs differ from classical rheumatic diseases in multiple aspects, and treatment should be individualized based on the severity. Close collaboration with oncologists is critical for preventing irreversible organ damage. This review summarizes the current evidence regarding the mechanisms and management of rheumatic irAEs with focus on arthritis, myositis, and vasculitis. Based on these findings, potential therapeutic strategies against rheumatic irAEs are discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Immunology, Osaka Metropolitan University Graduate School of Medicine, Osaka 565-0871, Japan.
- Preemptive Medicine and Lifestyle Related Disease Research Center, Kyoto University Hospital, Kyoto 606-8397, Japan.
- Department of Orthopaedic Surgery, Osaka Metropolitan University Graduate School of Medicine, Osaka 565-0871, Japan.
ORCID-Profile: Ryu Watanabe
Förderung
- JSPS KAKENHI
- a Grant for Promoting Research and Survey in Rheumatic Diseases by Japan Rheumatism Foundation
- Grant for Promoting Research and Survey in Rheumatic Diseases by Japan Rheumatism Foundation to RW
Zitieren
APA
Dang, Q. M., Watanabe, R., Shiomi, M., Fukumoto, K., Nobashi, T. W., Okano, T., Yamada, S., & Hashimoto, M. (2023). Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. International Journal of Molecular Sciences, 24(6), 5643. https://doi.org/10.3390/ijms24065643
Vancouver
Dang QM, Watanabe R, Shiomi M, Fukumoto K, Nobashi TW, Okano T, et al. Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update. International Journal of Molecular Sciences. 2023;24(6):5643. doi:10.3390/ijms24065643
BibTeX
@article{Dang2023,
author = {Dang, Quang Minh and Watanabe, Ryu and Shiomi, Mayu and Fukumoto, Kazuo and Nobashi, Tomomi W and Okano, Tadashi and Yamada, Shinsuke and Hashimoto, Motomu},
title = {Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors—A 2023 Update},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {6},
pages = {5643},
doi = {10.3390/ijms24065643}
}
EUVIMED